Mining and research of adverse reaction signals of pneumonia vaccines based on US Vaccine Adverse Event Reporting System

doi:10.19803/j.1672-8629.20210956

Abstract

Abstract: Objective To provide reference for rational and safe use of pneumonia vaccines by mining and studying the adverse reaction signals of pneumonia vaccines. Methods The reporting odds ratio (ROR) and the proportional reporting ratio (PRR) were used to analyze the adverse reaction reports collected by the American Vaccine Adverse Reaction Event Reporting System (VAERS) between January 1, 2010 and December 31, 2019, while adverse reaction signals related to pneumonia vaccines were mined. Results Thirty-six ADR signals associated with 23-valent pneumonia polysaccharide vaccines were obtained using both the ROR and PRR method, seven of which were not mentioned in specifications before, and ADR with the highest signal intensity were related to leukocytosis. A total of 103 ADR signals of 13-valent pneumococcal polysaccharide conjugate vaccines were obtained using ROR, compared with 102 signals by PRR. Thirty-six of the ADR signals were not mentioned in any specifications before, and ADR with relatively high signal intensity centered on gastrointestinal diseases, infections and invasive diseases, systemic diseases, and various reactions at the administration site. Conclusion It is suggested that patients should be closely monitored for adverse reactions, especially new ADR that are not mentioned in specifications, and immediate interventions should be enforced when pneumonia vaccines are used.

Key words: pneumonia vaccine, adverse drug reactions, VAERS, reporting odds ratio, proportional reporting ratio, signal mining

CLC Number:

R978
R994.1

LIU Yantao, ZHANG Lingli, LIN Yunzhu, CHEN Li, WANG Li. Mining and research of adverse reaction signals of pneumonia vaccines based on US Vaccine Adverse Event Reporting System[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 96-100.

References

[1] Chinese Preventive Medicine Association, Vaccine and Immunology Branch of the Chinese Preventive Medicine Association. Expert consensus on immunoprophylaxis of pneumococcal disease (2020 version)[J]. Chinese Journal of Preventive Medicine(中华预防医学杂志), 2020, 54(12): 1315-1363.
[2] O'BRIEN KL, WOLFSON LJ, WATT JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates[J]. The Lancet, 2009, 374(9693): 893-902.
[3] Ministry of Health, People's Republic of China. Report on Women and Children's Health Development in China(2011)[R/OL]. (2011-09-21)[ 2011-10-21]. http://www.gov.cn/gzdt/att/att/site1/20110921/001e3741a4740fe3bdab01.pdf.
[4] SUN JF, YAO HY, YU SC, et al.Disease Burden of three kinds of bacterial meningitis in China, 1990 and 2010[J]. Disease Surveillance(疾病监测), 2015, 30(12): 1008-1013.
[5] WHO. Meeting of the Immunization Strategic Advisory Group of Experts, November 2007-conclusions and recommendations[J]. Weekly Epidemiology Record, 2008, 83(1): 1-15.
[6] HABER P, ARANA J, PILISHVILI T, et al.Postlicensure surveillance of 13valent pneumococcal conjugate vaccine (PCV13) in adults aged 19 years old in the United States, Vaccine Adverse Event Reporting System (VAERS), June 1, 2012December 31, 2015[J]. Vaccine, 2016, 34(50): 6330-6334.
[7] MILLER ER, MORO PL, MARIA C, et al.Postlicensure safety surveillance of 23valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System(VAERS), 1990-2013[J]. Vaccine, 2016, 34(25): 2841-2846.
[8] Vaccine Adverse Event Reporting System. VAERS data use guide[EB/OL]. (2020-11-30)[2021-02-26]. https://vaers.hhs.gov/docs/VAERSDataUseGuide_November2020.pdf.
[9] Center For Drug Evaluation,NMPA. Medical dictionary for regulatory activities, MedDRA[EB/OL].(2020-11-30)[2021-01-27]. http://www.cde.org.cn/ichWeb/learnMedDRA/learnMedDRA.jsp.
[10] REN JT, WANG SF, HOU YF, et al.Common signal detection methods of adverse drug reaction[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2011, 8(5): 294-298.
[11] CHENG Y, CHEN C, YU CF, et al.Mining and analysis of adverse drug reaction signals caused by tacrolimus based on the U.S.Food and drug administration adverse event reporting system database[J]. Evaluation and Analysis of Drug-use in Hospitals of China(中国医院用药评价与分析), 2020, 20(5): 620-624.
[12] WANG YY, CHEN L.Data-mining of ADR signals for human papilloma virus tetravalent vaccine based on FDA Vaccine Adverse Event Reporting System[J]. Herald of Medicine(医药导报), 2020, 39(1): 17-21.
[13] LIANG Y, FANG LL.Analysis of technical specifications and regulatory regime for vaccines in the United States[J]. China Food ＆ Drug Administration Magazine(中国食品药品监管), 2019 (3): 14-21.
[14] GONG L, PAN LY, LIU Y, et al.Detection and evaluation of post-marketing safety alert signals for human papillomavirus 9-valent vaccine based on US Vaccine Adverse Event Reporting System(VAERS)[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(8): 478-486, 491.
[15] WU BH,YAN K,CHEN L.Study on ADR signal detection of dasatinib and imatinib[J]. China Pharmacy(中国药房), 2018, 29(20): 2840-2844.